Loading...

HRTX HERON THERAPEUTICS INC Management Changes 8-K Filing

HRN

HRTX

HERON THERAPEUTICS INC

(HRTX)

2023 8-K

Financial Results Announced

Financial Results Announcement

Financial Results Report

Director Appointment

Stockholder Approvals

New Office Lease

Tax Benefit Plan

Debt Restructuring

Financial Statements

Regulatory Compliance

Earnings Results

Loan Agreement Amendment

Headquarters Relocation

Patent Litigation Win

Earnings Announcement

Board Appointment

Earnings Release

FDA Acknowledgment of ZYNRE...

Annual Meeting Approval

Earnings Release

Earnings Release

FDA Approval for ZYNRELEF

Co-Promotion Agreement

Notice of Generic Version

Resignation of Director

Earnings Release

Earnings Release

Equity Offerings

Appointment of CFO

Management Changes

Financial Results Announcement

Departure of Directors and ...

Appointment of CEO and Chai...

External Links:

Heron Therapeutics announced the resignation of Kimberly Manhard as Executive Vice President, Drug Development, and the appointment of William Forbes as Executive Vice President, Chief Development Officer. The company also approved an amendment to increase the total number of shares of common stock authorized for issuance.

AI Assistant

HERON THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.